Current status of opiate receptors and their agonists is reviewed -basic aspects of receptor theory, the importance of stereospecificity in drug-receptor interactions and the role of 'second messengers' in drug action. The three classes of endogenous opioids, originating from three distinct genes, are discussed: pro-opiomelanocortin, giving rise to (3-endorphin, ACTH and various MSHs; pro-en kephalin, giving methionine en kephalin and leucine en kephalin; and prodynorphin; their anatomical distribution and the main classes of receptors with which they interact, the l1-receptor, with a high affinity for met-en kephalin and (3-endorphin (as well as morphine and dynorphin A); the o-receptor for which the primary ligand is leu-enkephalin; and the JC-receptor which is the main target for the dynorphins. Functional roles for endogenous opioids are considered. Essentially they are inhibitory to target neurones, depressing motor reflexes, baroreflexes and nociception. They also have roles in the response to physical and psychological stress.
There has, in recent years, been a great increase in our understanding of pain: this change has involved a confluence of physiology and pharmacology. Central to the pharmacology have been the age-old opiate analgesics and modern concepts of drug receptors.
Broadly speaking there are two possible answers to the question: 'Why do opiates act as analgesics?' The first is that, quite fortuitously, they react with some component of the nervous system which (perhaps atavistically or perhaps equally fortuitously) has some association with nociception (the perception of what we call pain). The second is that in some way the combination is with a molecule of some genuine functional importance, perhaps a receptor for a neurotransmitter. For several reasons the latter answer is the more attractive. Apart from the fact that it offers the possibility of some logical framework for drug action, it has to its credit similarities in the current state of our knowledge of other drugs, for example, those acting at catecholaminergic or histaminergic sites within the body.
Receptor concepts
It has become a fundamental concept of modern pharmacology that the biological activity of a drug almost invariably results from its interaction with some specific macromolecule in the the target tissue, typically a protein. This macromolecule is the drug receptor: it is a recognition site for the drug and is the intermediary between the presence of the drug in the biophase and the biochemical or biophysical events which lead to the biological response to the drug. Such an agent is, of course, an agonist. If the drug-receptor interaction leads no further (but denies access to any agonists) the drug is an antagonist. Implicit in this scheme is the fact that the agonist drug is commonly a surrogate for some natural ligand which it will mimic.
Most of these receptors are associated with membranes, either the membrane which partitions the cytoplasm from the extracellular fluid, or some intracellular membrane, e.g. the cytoplasmic reticulum or secretory vesicles. Other receptor sites are associated with the DNA of the cell nucleus. These membranes are lipid in nature and only those compounds that are lipid-soluble (e.g. the steroid hormones) can readily permeate to the interior of the cell. On account of their protein nature receptors afford lipid-insoluble substances a means of influencing events in the interior of the cell.
The properties of t1lese proteins depend upon their primary structure, i.e. the amino acids which they contain and the sequence in which these occur in the polymer molecule. Because some of the constituent acids carry a nett charge, attractions and repulsions occur within the molecule which determine the threedimensional structure of the protein, in particular whether certain amino acids lie together and might constitute a functional cluster or centre, e.g. the active site for an enzyme or the recognition site for a hormone, neurotransmitter or drug. This site might act as the essential receptor.
Once combination with the drug has occurred a significant change in this stereostructure might follow. This kind of change occurs with certain sorts of enzyme activation, e.g. of proteolytic enzymes by the removal of a short peptide chain from the molecule or by what is called allosteric activation following the combination of an appropriate activator at a specific site. This change in conformation (it opens up) provides readier access to the enzymatic locus of the enzyme.
When the molecule acts as a receptor, this allosteric change (initiated when the drug combines with that part of the protein which faces the extracellular fluid) might activate an enzymatic site on the part of the protein facing towards the intracellular fluid and lead to the synthesis of what is called a 'second messenger', the hormone or transmitter being the 'first messenger'. Cyclic AMP is such a 'second messenger' and its production will, in turn, influence the metabolism in some way that is particular for that cell. The change might, alternatively, open a gate which controls access to a channel or pore of some type (which might itself be part of the receptor molecule) in the membrane, creating an aqueous zone running through the membrane through which lipid-insoluble material might pass, especially ions which will eventually alter the electrical polarisation of the cell, thereby exciting or inhibiting the cell.
The reaction of the agonist with the receptor site and the functional result are quite separate events, depending upon the properties of the proteins involved. As we know from the existence of muscarIniC and nicotinic cholinergic synapses, the same agonist can combine with different protein receptors. We also know from the neuromuscular junction and the sinoatrial node that the same transmitter may be excitatory or inhibitory.
Within this scheme, therefore, an antagonist is a compound that is structurally sufficiently similar to the transmitter, hormone or drug to be able to achieve a combination with the 'recognition' site but not to achieve the particular conformational change which will produce the functional biological effect.
Opiate receptors
Where a drug interacts with such a receptor molecule, it is reasonable to postulate that there is some endogenous compound which normally combines at that locus, i.e. a natural ligand for the receptor. It was logical to apply this kind of thinking to the opiate drugs, especially with the discovery 1,2 that their actions are stereospecific: only the laevo-rotatory form (-morphine) is active. This view was strengthened when drugs containing a radioactive element as a label became available. It was found that (1) only the laevo-rotatory isomer binds with high affinity (i.e. with specificity) to nervous tissue, and (2) this binding is quite heterogeneous in its distribution within the nervous system, suggesting a functional specialisation and a probable function as neurotransmitters by the natural ligands. Figure 1 illustrates these points.
Panel B shows ileal contractions in response to electrical stimulation of the tissue in vitro.
The laevo-rotatory drug (enantiomer) produces a clear inhibition of the contractions whereas, even at lOO-fold higher doses, the dextrorotatory drug produces no such reduction in the contractile force. Panel D shows the efficacy of these enantiomers of morphine in producing analgesia. A battery of tests of nociception was employed after Injection of minute doses of drug into the periaqueductal grey matter of the mesencephalon (a region chosen on account of its known association with opiate analgesia): even with eight times the dosage, the + morphine produced substantially less analgesia than -morphine. Panels A and C suggest the mechanism underlying these effects. In A, preparations of brain membranes have been labelled with radioactive dihydromorphine and then exposed to + morphine or -morphine. As the concentration of (non-radioactive) morphine is increased different effects are seen with the two enantiomers. With themorphine the amount of bound radioactivity (presumed to be bound to opiate receptors) declines progressively from morphine concentrations of 10 -10 molar to 10 -7 molar. This is because the morphine is generally inhibitory to neural activity: see below). Note that the ( + I-morphine has virtually no effect and that the potency is less than 10 -3 that of the ( -I-isomers. D. Mean scores in a battery of tests for analgesia following injection of ( + I-morphine or ( -I-morphine into the periaqueductal grey matter of rats. Note that the dose of ( + I-morphine (for a much smaller effect) is 80 I'g whereas that for (-I-morphine is 10 I'g. This region of the mesencephalon is considered an important site of morphine action. competing with the dihydromorphine and displacing it from the receptor binding sites.
The + morphine is incapable of this competitive binding and affects the level of radioactivity only at the relatively high concentration of 10 -5 molar. There is thus a 10 4 -105 difference in the receptors' affinity for these entantiomers. Panel C shows that -morphine but not + morphine reduces the intracellular concentrations of cyclic AMP on a glioma cell preparation, so only the laevorotatory drug would exert a functional effect (which could be some inhibition of a cellular activity, as with the reduction of gut contractility). When opiate antagonist drugs began to be synthesised the same stereospecificity was found. The potency of -naloxone as an antagonist is 1,000-10,000 times that of
Endogenous /igands
The obverse of this coin is the nature of the compounds which normally bind to these stereospecific, putative receptor proteins, viz. the naturalligands. In his epoch-making paper 4 John Hughes wrote in 1975, 'If the brain does contain an endogenous morphine-like substance, this substance might be expected to have a similar effect' (to morphine) 'on these isolated tissues' (e.g. the ileum as in Figure I ). 'The crucial test of morphine-receptor agonist activity would be the ability of naloxone ... to block the effects of the endogenous material. ' Hughes made brain extracts, avoiding the error of some form of fortuitous specificity, by using brains from rabbits, guinea-pigs, rats and pigs. He examined the effects of these extracts on the contractions produced by electrical stimulation of the isolated vas deferens. His brain extracts produced a potent inhibition of these contractions ( Figure 2 ) and this inhibition (like the inhibition brought about by morphine) was abolished by the specific opiate antagonist naloxone. As Hughes observed, this was a crucial test since various other agents produce such an inhibition of these contractions of the vas. The list includes noradrenaline and dopamine which are certainly contained within the brain. At the end of that same year, Hughes and his colleagues reported 5 that the active agents in these brain extracts were two pentapeptides, chains of five amino acids, identical apart from the last in their sequence: tyrosine-glycineglycin e-pheny lalanine-methionine/leucine. They were called methionine-enkephalin and leucine-enkephalin, from their origin and their distinguishing amino acids. Hughes and other groups have found that the brain contains about four times as much met-enkephalin as leu-enkephalin. In the next year, Li and Chung in California isolated [3-endorphin,6 a 31-amino acid peptide (which happens to contain the metenkephalin sequence). It too has analgesic properties which are blocked by naloxone. It was first discovered in the pituitary but has since been found in hypothalmic neurones: its distribution is restricted compared with the enkephalins.
Since then a plethora of pep tides have been discovered with opioid (the term for 'opiatelike') properties and the field has become very confusing indeed, akin to the situation with adrenergic agonists and antagonists without the clarifying principles of Ahlquist's alpha/beta classification. One of the most important was discovered by Goldstein's group in California in 1979, the most potent analgesic dynorphin. 7 It has been left to developments in molecular biology to impose some order. There appear to be three families of these opioid peptides, each stemming from a distinct gene. 8 These genes code for the synthesis of far larger protein precursors from which the various active peptides are clipped out: this is now recognised as the usual method for producing such peptides (e.g. hormones).
One such family is the pro-opiomelanocortin line. As Figure 3 shows this large protein is the source of the three melanocyte-stimulating hormones as well as [3-endorphin and ACTH. These latter are in some circumstances secreted concomitantly. 9 The second group constitute the pro-en kephalin family: this precursor gives rise to four molecules of orthodox metenkephalin and two variants as well as a molecule of leu-enkephalin (hence the 4: 1 ratio mentioned above). The third precursor gene/parent protein (pro-dynorphin) gives rise to a number of dynorphin molecules of different amino acid chain lengths. Table 1 shows the sequences of some members of these families and a striking feature is that they all contain the sequence of one or other pentapeptide enkephalin. However, contrary to what one might initially think, we are not dealing with incomplete hydrolysis of precursor proteins leading to this array with common structural features. The intracellular enzymes which are responsible for the release of the functional peptides from the precursors (endopeptidases) operate only at pairs of basic amino acids (lysine-arginine or lysine-lysine) and on that basis there is no scope for further hydrolysis of the peptides in Table 1 . Further, the entire Anaesthesia and Intensive Care. Vol. 15, No. I, February, 1987 amino acid sequence of pro-enkephalin has been determined and in no case is the en kephalin sequence followed by the same amino acids as follow it in f3-endorphin. Since these sequences are determined by the base sequences of the DNA it follows that f3-endorphin must be the result of the expression of a different gene from that coding the enkephalins, even if, in earlier evolutionary eras, these genes may have had a common origin.
Anatomy
Not only are these substances distinct in their genetic provenance, they originate in different cells in different parts of the nervous system. Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle Dynorphin A-(l-/7J: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-Trp-Asp-Asn-Gln Dynorphin B-(l-I3).· Tyr-Gly·Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr same vesicles as the catechol amines: in some species the opioid concentration is well below that of the catechol amine while in others it is far greater 10); in the gastrointestinal tract (especially in the myenteric plexus), in perhaps 25% of the neurones; in spinal cord, in the marginal layer and substantia gelatinosa of the dorsal horn where it has an intimate association with the primary sensory afferents; in the central nervous system in a wide array of locations but in particular in the cell bodies of globus pallidus, amygdala, supraoptic and paraventricular nuclei of the hypothalmus, neocortex. In virtually every region there is a protean distribution of fibres and terminals that contain enkephalins: cerebral cortex, striatum, periaqueductal grey matter, locus coerulus, raphe nuclei to mention a mere few. A plethora of functions seems to be involved but the variety of projections is, as yet, surely only incompletely mapped. 3. The dynorphins, the most recently discovered family, have been identified in the gut, the hypothalamm and posterior pituitary and brain stem. 
Receptor classes
Before the existence of these agonist classes was established, it was becoming increasingly apparent that there are also different classes of receptors (just as there are receptor classes and sub-types for histamine, catecholamines, acetylcholine etc.). Several classes have been proposed and at present most workers in the field regard three as well established:
(a) the j..I-receptor, named from morphine for which it has a high affinity; {3-endorphin is very potent at j..I-receptors and it has been suggested that the endogenous ligand that is specifically targeted to j..I-receptors is metenkephalin;
(b) the d-receptor is also a target for {3-endorphin (which may slightly prefer it to the j..I-receptor) and for leu-enkephalin which is primarily d in its activity. One of the dynorphins (named dynorphin A 1-8) also has d capability; (c) the lC-receptor (named from ketocyclazocine) is the main target for the dynorphins though dynorphin A 1-13 is also potent at j..I-receptors. 11, 12 The ratio of the opiate binding sites j..I:d:lC in guinea pig brain has been estimated to be 25:45:30. 13 It is clear that, attractive though it would have been, one cannot relate the three ligand families simply to the three receptor classes.
These classes have been established by a variety of pharmacological techniques. Martin's group in 1976 14 classified various opioid drugs according to the patterns of their actions in spinalised dogs. Their criteria included whether in morphine-dependent animals other opioid drugs would precipitate or suppress the withdrawal syndrome; whether cross-tolerance occurred between different drugs; by the presence or absence of certain physiological responses (e.g. morphine-induced bradycardia in these dogs whereas ketazocine had no effect on heart rate).
Hughes, Kosterlitz and their collaborators II used isolated tissues and found, when they compared potencies on guinea pig ileum and mouse vas deferens, that there were clear differences: ~-endorphin was equipotent, the two enkephalins were much more potent on the vas and morphine was clearly more potent on the ileum. It seemed obvious that these different agents were not interacting with the same receptors.
Another approach is the use of binding studies with radioactive drugs to quantify the amount of specific binding that occurs with different tissues and different drugs. Figure 4 shows the amount of such binding to mouse membranes as the preparation is exposed to increasing concentrations of ~-endorphin; the curve flattens off, a pattern seen in all instances where specific site binding occurs (e.g. with enzymes, active-transport systems). When these results are re-plotted as a Scatchard plot we see a single straight line, indicating that we are observing only a single type of binding. 15 That is not always the case. Figure 5 shows a different result from a study of the binding of radioactive naloxone to membrane preparations from mouse brain. The binding from saline-treated animals shows two distinct parts with the Scatchard plot, indicating two quite separate receptor populations with distinct binding (i.e. chemical) properties; the binding in animals treated with a long-acting derivative of naloxone shows that one of these populations (the one with the higher affinity for Anaesthesia and Intensive Care. Vol. 15 . No. /, February, 1987 naloxone) was no longer able to bind the radioligand. 16 • Saline The open circles are results from animals pre-treated with naloxazone, a long-acting narcotic antagonist. There is now a single straight line with the Scatchard plot: the highaffinity receptors are inaccessible to naloxone. These high-affinity sites seem to be associated with morphine analgesia (the naloxazone-treated animals showed persistent antagonism to this analgesic) but the lethal effects of morphine (respiratory depression) seem associated with the (unblocked) low-affinity receptors.
(From Pasternak et al. 16) One cannot be certain that this kind of binding is necessarily to functional receptors of the kind discussed earlier though Figure 6 suggests that this is highly likely to be the case. 17 The figure shows that, for a variety of drugs, specific binding increases with drug dose (the binding being again shown by an increasing displacement by non-radioactive drug of previously bound radio-naloxone); some of this binding seems to have an important biological effect, viz: the reduction of the concentration of the important intracellular 'secondmessenger', cyclic AMP. (It will be shown later that the opiates are generally inhibitory in their actions.)
The receptor specificity revealed by studies of this kind is the basis for the hope that new drugs may be synthesised which have analgesic properties but no addictive potential or depression of respiration. Functional roles of opioid receptors 1. Studies on single neurones Figure 7 shows an interesting finding from Duggan's laboratory in Canberra. 18 When metenkephalin is injected into the substantia gelatinosa of the spinal cord (where the primary afferent terminals form their synapses with this cell) the pain impulses are clearly filtered out but the (non-noxious) mechanosensitive input is not affected. The action of en kephalin is promptly and potently blocked by naloxone, the effect of which is seen to decline with time. Morphine has the same specific effect in this region where the opiate receptors are probably located on the primary terminals (hence allowing the selective filtering of the sensory inputs). Motor neurones are also under inhibitory influence from opioids. Figure 8 shows that, in a variety of monosynaptic reflexes (recorded from the ventral nerve rootlets of an anaesthetised cat) the reflex response is increased by naloxone. 19 Various brainstem neurones have also been studied in which different opioid agonists have powerfully depressed neuronal firing, effects which are antagonised by naloxone. The same pattern has been seen in neurones of the myenteric plexus in the gut.
Cardiovascular control
There are numerous putative roles for these neurotransmitters and transmitter modulators among which are functions in cardiovascular control. The literature on the actions of the opiates is vast and study is complicated by the fact that the pharmacological responses to these peptides depend on species, dose, route and site of administration as well as the presence or absence of anaesthetics. 20 The peptides have been shown to produce tachycardia or bradycardia as well as hypertension or hypotension. For example, when an analogue of leu-enkephalin was injected (50 J1g) into the fourth ventricle of unanaesthetised rats there was a 10-15 mmHg rise in mean arterial pressure but in rats anaesthetised with pentobarbitone pressure fell by a comparable 19) amount. In the unanaesthetised animal, injection into the third ventricle evoked no change over about 45 minutes but there was a fall of approximately 30 mmHg when the animals were anaesthetised. The peptides also attenuate the baroreflex while naloxone exaggerates this compensatory mechanism. It was logical, therefore, to look for a role for these opioids in shock. With haemorrhagic shock, for example, naloxone was found to improve blood pressure and survival in rats subjected to severe, acute haemorrhage. 21 Similar improvement has been found in dogs, cats, rabbits and monkeys. 20 It is doubtless significant that in shock, plasma levels of f3-endorphin (probably of pituitary origin) and en kephalin (from the adrenal medulla) are increased. 22 Similarly, endotoxic shock seems to involve endogenous opioids.
Response to stress
Although the term 'stress' may have a flexible definition, it is accepted that the anterior pituitary-adrenal cortical axis is important in the response to various forms of stress. Endogenous opioids are now known to be involved as well.
Stress evokes concomitant secretion of ACTH and f3-endorphin from the anterior pituitary (logical in view of their proopiomelanocortin origins)9 and there is now a well-recognised form of analgesia which is . . The mice were swum for three minutes in water at 21 QC and tested three minutes later. Testing was by the hotplate method: the measurement of the time for the appearance of a fast-flick of a hind limb after the animal is placed on a hotplate (56 QC). Control values are shown by the shaded line; an increased latency indicates analgesia. This effect is wholly abolished by naloxone at very low dosage. (From Cooper and Carmody. 23) induced by stress, involving endogenous opioids. Work in my own laboratory has shown that both the standard psychologists' electroshock to the feet and swimming (in mice) produce a potent and very naloxone-sensitive analgesia 23 which is quite long-lasting (as shown in Figure 9 ). In addition, this shock greatly increases the animals' sensitivity to pentobarbitone, with 'sleep' (i.e. loss of the 'righting reflex') occurring in the stressed animals at plasma and brain levels about half those necessary in unstressed animals. 24 In conclusion a highly selective glimpse at some of the functions of the endogenous opioids and the underlying mechanisms has been presented. The plethora of effects and the complexity of these mechanisms can only increase, as would be expected with agents which are mimicked by a drug which has for so long been so important to anaesthetists and other medical practitioners.
